162744-60-7

Basic information

• Product Name: 4-BROMO-2,6-DIFLUOROBENZYL BROMIDE
• Synonyms: 4-BROMO-2,6-DIFLUOROBENZYL BROMIDE;5-BROMO-2-(BROMOMETHYL)-1,3-DIFLUOROBENZENE;4-broMo-2,6-difluorobenzyl briMide;Benzene, 5-broMo-2-(broMoMethyl)-1,3-difluoro-;4-Bromo-2,6-difluorobenzyl bromide 98%;5-Bromo-2-(bromomethyl)-1,3-difluorobenzene, alpha,4-Dibromo-2,6-difluorotoluene;4-Bromo-2,6-difluorobenzylbromide98%
• CAS NO: 162744-60-7
• Molecular Formula: C₇H₄Br₂F₂
• Molecular Weight: 285.91
• Product Categories: Pharmaceutical intermediate;NVP-BSK 805
• Mol File: 162744-60-7.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 244℃
• Flash Point: 101℃
• Appearance: /
• Density: 1.991
• Vapor Pressure: 0.0498mmHg at 25°C
• Refractive Index: 1.562
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• Sensitive: Lachrymatory
• CAS DataBase Reference: 4-BROMO-2,6-DIFLUOROBENZYL BROMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-BROMO-2,6-DIFLUOROBENZYL BROMIDE(162744-60-7)
• EPA Substance Registry System: 4-BROMO-2,6-DIFLUOROBENZYL BROMIDE(162744-60-7)

Safety Data

• Hazard Codes: C
• Hazardous Substances Data: 162744-60-7(Hazardous Substances Data)

Usage

General Description

4-Bromo-2,6-difluorobenzyl bromide is a chemical compound that belongs to the category of benzyl bromides. It is a colorless to light yellow liquid with a molecular formula of C7H5Br2F2 and a molecular weight of 261.924 g/mol. This chemical is used as a reagent in various organic synthesis reactions, particularly in the pharmaceutical and agrochemical industries. It is known for its ability to introduce the benzyl bromide moiety into organic compounds, making it an important building block for the synthesis of complex molecules. Additionally, it is also used in the preparation of benzyl bromides for use as intermediates in organic synthesis. However, it is important to handle this compound with care, as it is corrosive and can cause skin and respiratory irritation.

InChI:InChI=1/C7H4Br2F2/c8-3-5-6(10)1-4(9)2-7(5)11/h1-2H,3H2

Upstream product

• 162744-59-4 (4-bromo-2,6-difluoro-phenyl)methanol 
• 869361-54-6 4-bromo-2,6-difluorobenzyl methanesulfonate 
• 183065-68-1 4-bromo-2,6-difluorobenzoic acid 
• 537013-51-7 4-bromo-2,6-difluorobenzaldehyde 

Downstream Products

• 1610472-40-6 2-(4-bromo-2,6-difluorobenzyl)-6-tert-butyl-8-fluoro-2H-phthalazin-1-one 
• 1610472-23-5 6-tert-butyl-2-[2,6-difluoro-4-(2-oxo-1,2-dihydro-pyridin-4-yl)-benzyl]-8-fluoro-2H-phthalazin-1-one 
• 1610472-41-7 6-tert-butyl-2-[2,6-difluoro-4-(2-methoxypyridin-4-yl)benzyl]-8-fluoro-2H-phthalazin-1-one 
• 537033-52-6 2-(4-bromo-2,6-difluorophenyl)acetonitrile 

Relevant articles and documents

CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS

The present disclosure relates to modulators, such as inhibitors, of at least one pathway chosen from USP28 and USP25, pharmaceutical compositions comprising the inhibitors, and methods of using the inhibitors. The modulators, such as inhibitors, of at least one pathway chosen from USP28 and USP25 can be useful in the treatment of cancers, among other ailments.

NOVEL COMPOUNDS AS REARRANGED DURING TRANSFECTION (RET) INHIBITORS

This invention relates to novel compounds which are inhibitors of the Rearranged during Transfection (RET) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of gastrointestinal sensitivity, motility and/or secretion and/or abdominal disorders or diseases and/or treatment related to diseases related to RET dysfunction or where modulation of RET activity may have therapeutic benefit including but not limited to all classifications of irritable bowel syndrome (IBS) including diarrhea-predominant, constipation-predominant or alternating stool pattern, functional bloating, functional constipation, functional diarrhea, unspecified functional bowel disorder, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disorders, functional gastroduodenal disorders, functional anorectal pain, inflammatory bowel disease, proliferative diseases such as non-small cell lung cancer, hepatocellular carcinoma, colorectal cancer, medullary thyroid cancer, follicular thyroid cancer, anaplastic thyroid cancer, papillary thyroid cancer, brain tumors, peritoneal cavity cancer, solid tumors, other lung cancer, head and neck cancer, gliomas, neuroblastomas, Von Hippel-Lindau Syndrome and kidney tumors, breast cancer, fallopian tube cancer, ovarian cancer, transitional cell cancer, prostate cancer, cancer of the esophagus and gastroesophageal junction, biliary cancer, adenocarcinoma, and any malignancy with increased RET kinase activity.

INHIBITORS OF BRUTON'S TYROSINE KINASE

This application discloses compounds according to generic Formula (I): wherein all variables are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation such as rheumatoid arthritis. Also disclosed are compositions containing compounds of Formula I and at least one carrier, diluent or excipient.